MEC Practice Academy 11.19
News|Articles|November 17, 2026

White House withdraws Heidi Overton's FDA nomination on eve of Senate committee vote

Fact checked by: Keith A. Reynolds
Listen
0:00 / 0:00

Key Takeaways

  • Senate math on HELP made confirmation unlikely, with Republican skepticism and no expected Democratic support prompting withdrawal before committee action.
  • Bill Cassidy emphasized leadership capability and vaccine policy, criticizing support for breaking up combination vaccines and pressing on independence from presidential pressure.
SHOW MORE

The decision leaves the FDA under acting leadership as Senate Republicans race to confirm nominees before Democrats take control in January.

The White House on Nov. 17 withdrew the nomination of Heidi Overton, M.D., Ph.D., to lead the Food and Drug Administration (FDA), one day before the Senate Health, Education, Labor and Pensions (HELP) Committee was scheduled to vote on whether to send her to the full Senate.

Overton "lacks the support on the Hill to move forward with her confirmation," a senior administration official told Axios, which first reported the decision late Nov. 17.

Republicans hold a one-vote majority on the committee, so a single GOP defection would have sunk the nomination if every Democrat voted no, according to The Hill. No Democrats were expected to back her, and Sens. Susan Collins (R-Maine) and Lisa Murkowski (R-Alaska) had not said how they would vote, CBS News reported hours before the withdrawal.

Overton, deputy director of the White House Domestic Policy Council, was nominated Aug. 19 to replace Marty Makary, M.D., who resigned as commissioner in May. Kyle Diamantas, J.D., has led the FDA as acting commissioner since Makary's departure, CBS News reported.

Overton trained as a general surgery resident at Johns Hopkins, is board-certified in public health and general preventive medicine and served as a White House fellow from 2019 to 2020, according to the America First Policy Institute, where she was chief policy officer before rejoining the administration.

She holds a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health.

Cassidy's doubts centered on vaccines

On Aug. 19, the day Trump announced the pick, HELP Committee Chair Sen. Bill Cassidy, M.D. (R-Louisiana), wrote on social media that while he respected Overton's experience as a physician, her "lack of managerial experience does not prepare her well" to lead an agency already dealing with staffing and morale problems, according to States Newsroom.

In the same post, Cassidy called her support for Trump's plan to break up combination vaccines, including the measles, mumps and rubella (MMR) shot, "almost disqualifying," The Associated Press reported. The plan was part of an executive order on childhood vaccines that Trump signed Aug. 10; Overton spoke at the Oval Office signing.

At her Sept. 24 confirmation hearing, Cassidy told Overton that Robert F. Kennedy Jr., secretary of the Department of Health and Human Services (HHS), had backed away from vaccine-access promises he made to the senator, then asked what she would do if Trump pushed her to break commitments she made to the committee.

Overton said she would give the president her best advice and follow the legal requirements of the commissioner's role, Fierce Biotech reported.

She told the panel the MMR vaccine and every other vaccine on the U.S. market are safe and effective, according to Source NM. She declined to say explicitly that Trump was wrong about the MMR vaccine's safety, the AP reported.

Cassidy lost his June primary and has weeks left in his term, the AP reported. Asked about the nomination by Face the Nation on Nov. 15, he said he was still working the phones and noted that failing to confirm a commissioner would mean relying on acting leadership, CBS News reported.

The same day, he said he had heard from people who think deeply about the FDA "who have said it's better to have a steady hand," while others disagreed, according to The Hill.

Abortion pill and vaping questions

Sen. Josh Hawley (R-Missouri) questioned whether Overton's hearing statements on mifepristone matched what the administration was arguing in ongoing litigation, Government Executive reported.

Sen. Patty Murray (D-Washington) asked about a 2023 article in which Overton called mifepristone dangerous to women, according to Roll Call. Overton answered that the drug "has met the safety and efficacy determinations of the FDA" and said she did not want to prejudge the agency's ongoing safety review.

Cassidy told Overton he wanted the next commissioner to require an in-person ultrasound before mifepristone is dispensed and to have physicians report adverse events tied to the drug, Roll Call reported.

Murkowski warned that requiring in-person dispensing would put a rural state such as Alaska in a difficult position, according to the Alaska Beacon.

Multiple Republican senators had concerns about Overton's stances on abortion, vaccines and vaping, ABC News reported. Overton sidestepped questions about a mifepristone safety study the administration had promised, and the anti-abortion group Susan B. Anthony Pro-Life America urged senators to delay her confirmation, CBS News reported.

The network also reported that Overton helped carry out Trump's pro-vaping policies on the Domestic Policy Council. Makary has said tobacco companies pressured him to approve fruit-flavored vapes and that he refused, according to CBS.

Opposition from Make America Healthy Again allies

Calley Means, a former HHS adviser and prominent voice in Kennedy's Make America Healthy Again (MAHA) movement, urged his followers to block the nomination. "Heidi Overton was the biggest block to MAHA policies I encountered in the government," Means said, according to CBS News.

Means accused White House aides, including Overton, of helping advance the Supreme Court's June 25 ruling that blocked thousands of lawsuits against the maker of the Roundup weedkiller, the AP reported.

White House spokesperson Kush Desai said in August that Overton had been integral to keeping the administration's policies "grounded in Gold Standard Science," Government Executive reported. Kennedy praised her "exceptional judgment" after the nomination, and two former FDA commissioners endorsed her, CBS News reported.

What comes next for the agency

The White House has talked with possible replacements, including candidates who could serve as acting commissioner without Senate confirmation, and Sen. Roger Marshall, M.D. (R-Kansas), is reportedly considering the job, CBS News reported. In September, a New York Times analysis of Kansas court records found that Marshall and the obstetrics practice he owned sued more than 700 former patients over unpaid bills across roughly two decades.

Republicans are trying to confirm Trump's pending nominees before the new Congress is seated in January, according to STAT. Democrats won control of the House and Senate in the Nov. 3 midterm elections.

The administration previously withdrew Dave Weldon, M.D., its original pick to lead the Centers for Disease Control and Prevention, and two surgeon general nominees, Janette Nesheiwat, M.D., and Casey Means, M.D. The FDA has lost about 20% of its employees since Trump took office, the AP reported.

If confirmed, Overton would have been responsible for steering the agency through new vaccine recommendations and revamped rare disease drug reviews, Bloomberg Government reported in August. The FDA is also reviewing the safety of mifepristone.


Related to this article

Qasim Faizan: ©WeBill Health
Starting Jan. 1, Medicare will pay 20% less for the lower-valued service when an office visit billed with modifier 25 falls on the same day as a zero-day global procedure. One claims report priced at local 2027 rates shows independent practices their exposure, and three documentation habits protect the visits that still qualify for full payment.